Franklin Biotechnology Mutual Fund Money Managers
| FTDZX Fund | USD 134.78 1.92 1.40% |
Break down of Franklin Biotechnology's management performance can provide insight into the fund's overall performance. Note that fund manager's attribution analysis is becoming a valuable factor that both investors and analysts use to determine the amount of risk that may be associated with Franklin Biotechnology's future under-performance.
| Evan McCulloch Executive Fund Manager |
| More |
Franklin |
Franklin Biotechnology Net Asset Comparison
Franklin Biotechnology Discovery is one of the top funds in net asset among similar funds. Total Asset Under Management (AUM) of Health category is currently estimated at about 71.41 Billion. Franklin Biotechnology claims roughly 1.42 Billion in net asset contributing just under 2% to all funds under Health category.
Franklin Biotechnology Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Franklin Biotechnology Price Series Summation is a cross summation of Franklin Biotechnology price series and its benchmark/peer.
Franklin Biotechnology Stakeholder
| Evan McCulloch | Fund Manager | Profile |
About Franklin Biotechnology Management Performance
The success or failure of an entity such as Franklin Biotechnology often depends on how effective the management is. Franklin Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Franklin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Franklin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
Please note that past performance is not an indicator of the future performance of Franklin Biotechnology, its manager's success, or the effectiveness of its strategy. The performance results shown here may have been adversely or favorably impacted by events and economic conditions that may not prevail in the future. Therefore, you must use caution to infer that these results indicate any fund, manager, or strategy's future performance. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Franklin Biotechnology Discovery. Also, note that the market value of any mutual fund could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Franklin Biotechnology information on this page should be used as a complementary analysis to other Franklin Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.